Heily Carolina Ramirez Santana

Dr. Heily Carolina Ramirez Santana


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Journal of Autoimmunity
Verified
Journal Article
Open access
MRManuel Rojas
Manuel Rojas
PRPaula Restrepo-Jiménez
Paula Restrepo-Jiménez
DMDiana M. Monsalve
Diana M. Monsalve
YPYovana Pacheco
Yovana Pacheco
YAYeny Acosta-Ampudia
Yeny Acosta-Ampudia
Juan-Manuel AnayaJuan-Manuel Anaya
Juan-Manuel Anaya
Molecular mimicry is one of the leading mechanisms by which infectious or chemical agents may induce autoimmunity. It occurs when similarities between foreign and self-peptides favor an activation of autoreactive T or B cells by a foreign-derived antigen in a susceptible individual. However, molecular mimicry is unlikely to be the only underlying mechanism for autoimmune responses; other factors such as breach in central tolerance, non-specific bystander activation, or persistent antigenic stimuli (amongst others) may also contribute to the development of autoimmune diseases. Host genetics, exposure to microbiota and environmental chemicals are additional links to our understanding of molecular mimicry. Our current knowledge of the detailed mechanisms of molecular mimicry is limited by the issues of prolonged periods of latency before the appearance of disease, the lack of enough statistical power in epidemiological studies, the limitations of the potential role of genetics in human studies, the relevance of inbred murine models to the diverse human population and especially the limited technology to systematically dissect the human T-cell repertoire and B-cell responses. Nevertheless, studies on the role of autoreactive T-cells that are generated secondary to molecular mimicry, the diversity of the T-cell receptor repertoires of auto-reactive T-cells, the role of exposure to cryptic antigens, the generation of autoimmune B-cell responses, the interaction of microbiota and chemical adjuvants with the host immune systems all provide clues in advancing our understanding of the molecular mechanisms involved in the evolving concept of molecular mimicry and also may potentially aid in the prevention and treatment of autoimmune diseases.

1 June 2011 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
CCCristina Castellote
Cristina Castellote
RCRosario Casillas
Rosario Casillas
HSHeily Carolina Ramirez Santana
Heily Carolina Ramirez Santana
Francisco José PerezFrancisco José Perez
Francisco José Perez
Margarida CastellMargarida Castell
Margarida Castell
ÀFÀngels Franch
Àngels Franch
Human breast milk is the ideal nutrition for the newborn, and in addition to its nutritional contribution, necessary for infant growth and developmen

29 January 2018 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
YRYhojan Rodríguez
Yhojan Rodríguez
MRManuel Rojas
Manuel Rojas
YPYovana Pacheco
Yovana Pacheco
YAYeny Acosta-Ampudia
Yeny Acosta-Ampudia
HSHeily Carolina Ramirez Santana
Heily Carolina Ramirez Santana
Juan-Manuel AnayaJuan-Manuel Anaya
Juan-Manuel Anaya

26 September 2018 in Emerging Microbes & Infections
Verified
Journal Article
Open access
YAYeny Acosta-Ampudia
Yeny Acosta-Ampudia
DMDiana M. Monsalve
Diana M. Monsalve
YRYhojan Rodríguez
Yhojan Rodríguez
YPYovana Pacheco
Yovana Pacheco
JAJuan-Manuel Anaya
Juan-Manuel Anaya
HSHeily Carolina Ramirez Santana
Heily Carolina Ramirez Santana
Mayaro virus (MAYV), an enveloped RNA virus, belongs to the Togaviridae family and Alphavirus genus. This arthropod-borne virus (Arbovirus) is similar to Chikungunya (CHIKV), Dengue (DENV), and Zik...

1 March 2021 in Journal of Autoimmunity
Verified
Journal Article
Open access
YAYeny Acosta-Ampudia
Yeny Acosta-Ampudia
DMDiana M. Monsalve
Diana M. Monsalve
MRManuel Rojas
Manuel Rojas
YRYhojan Rodríguez
Yhojan Rodríguez
JGJuan Esteban Gallo
Juan Esteban Gallo
Juan-Manuel AnayaJuan-Manuel Anaya
Juan-Manuel Anaya
Convalescent plasma (CP) has emerged as a treatment for COVID-19. However, the composition and mechanism of action are not fully known. Therefore, we undertook a two-phase controlled study in which, first the immunological and metabolomic status of recovered and severe patients were evaluated. Secondly, the 28-day effect of CP on the immune response in severe patients was assessed. Nineteen recovered COVID-19 patients, 18 hospitalized patients with severe disease, and 16 pre-pandemic controls were included. Patients with severe disease were treated with CP transfusion and standard therapy (i.e., plasma recipients, n = 9) or standard therapy alone (n = 9). Clinical and biological assessments were done on day 0 and during follow-up on days 4, 7, 14, and 28. Clinical parameters, viral load, total immunoglobulin (Ig) G and IgA anti-S1-SARS-CoV-2 antibodies, neutralizing antibodies (NAbs), autoantibodies, cytokines, T and B cells, and metabolomic and lipidomic profiles were examined. Total IgG and IgA anti-S1-SARS-CoV-2 antibodies were key factors for CP selection and correlated with NAbs. In severe COVID-19 patients, mostly interleukin (IL)-6 (P = <0.0001), IL-10 (P = <0.0001), IP-10 (P = <0.0001), fatty acyls and glycerophospholipids were higher than in recovered patients. Latent autoimmunity and anti–IFN–α antibodies were observed in both recovered and severe patients. COVID-19 CP induced an early but transient cytokine profile modification and increases IgG anti-S1-SARS-CoV-2 antibodies. At day 28 post-transfusion, a decrease in activated, effector and effector memory CD4+ (P < 0.05) and activated and effector CD8+ (P < 0.01) T cells and naïve B cells (P = 0.001), and an increase in non-classical memory B cells (P=<0.0001) and central memory CD4+ T cells (P = 0.0252) were observed. Moreover, IL-6/IFN-γ (P = 0.0089) and IL-6/IL-10 (P = 0.0180) ratios decreased in plasma recipients compared to those who received standard therapy alone. These results may have therapeutic implications and justify further post-COVID-19 studies.

26 April 2016 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
Juan-Manuel AnayaJuan-Manuel Anaya
Juan-Manuel Anaya
HSHeily Carolina Ramirez Santana
Heily Carolina Ramirez Santana
MAMaria A. Alzate
Maria A. Alzate
NMNicolas Molano-Gonzalez
Nicolas Molano-Gonzalez
ARAdriana Rojas-Villarraga
Adriana Rojas-Villarraga
Autoimmune diseases (ADs) represent a heterogeneous group of disorders that affect specific target organs or multiple organ systems. These conditions share common immunopathogenic mechanisms (i.e., the autoimmune tautology), which explain the clinical similarities they have among them as well as their familial clustering (i.e., coaggregation). As part of the autoimmune tautology, the influence of environmental exposure on the risk of developing ADs is paramount (i.e., the autoimmune ecology). In fact, environment, more than genetics, shapes immune system. Autoimmune ecology is akin to exposome, that is all the exposures - internal and external - across the lifespan, interacting with hereditary factors (both genetics and epigenetics) to favor or protect against autoimmunity and its outcomes. Herein we provide an overview of the autoimmune ecology, focusing on the immune response to environmental agents in general, and microbiota, cigarette smoking, alcohol and coffee consumption, socioeconomic status, gender and sex hormones, vitamin D, organic solvents and vaccines in particular. Inclusion of the autoimmune ecology in disease etiology and health will improve the way personalized medicine is currently conceived and applied.